/Steris%20Plc%20logo%20and%20chart-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
STERIS plc (STE) is a global leader in infection prevention and sterilization solutions, headquartered in Dublin, Ireland. With a market cap of $23.9 billion, the company provides sterilization, surgical, and infection control products and services to hospitals, pharmaceutical companies, and medical device manufacturers. Its diverse portfolio includes sterilizers, surgical equipment, endoscope reprocessing systems, and consumable products.
STE is scheduled to report its Q2 earnings shortly. Ahead of the event, analysts expect the company to report a profit of $2.38 per share, representing a 11.2% increase from $2.14 per share in the same quarter of the previous year. The company has surpassed or matched Wall Street's bottom-line estimates in each of the past four quarters.
For fiscal 2026, analysts expect STE to report earnings of $10.07 per share, up 9.2% from $9.22 in fiscal 2025.
STE stock has climbed 7.9% over the past 52 weeks, lagging behind the S&P 500 Index's ($SPX) 15.1% gain but outperforming the Health Care Select Sector SPDR Fund’s (XLV) 4.1% decline over the same time frame.
On Sept. 25, STERIS shares slipped 3% after the U.S. Commerce Department launched a national security investigation into medical equipment imports under Section 232 of the Trade Expansion Act. The probe, which could lead to new tariffs on products like syringes, infusion pumps, and surgical instruments, sparked broad declines across the healthcare manufacturing sector as investors weighed potential impacts on supply chains and production costs.
Analysts’ consensus opinion on STE stock is fairly optimistic, with an overall “Moderate Buy” rating. Out of nine analysts covering the stock, six advise a “Strong Buy” rating and three recommend a “Hold.” The stock’s average analyst price target is $278.29, indicating a 15% potential upside from the current levels.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
